Using PET/MRI to improve current pre-clinical biomarkers in cancer

Treatments that involve activating a patient’s own immune system, immunotherapies, are becoming important cancer therapies. Unfortunately, doctors don’t always know the best way to combine these therapies to best treat patients and the current tools they have to evaluate treatment success don’t work well for immunotherapies. Molecular imaging, particularly magnetic resonance imaging (MRI) or positron emission tomography (PET) can help researchers learn more about how these therapies work and how best to combine them. Cubresa has developed advanced technology that allows researchers to simultaneously use PET and MRI for preclinical research.We will therefore be studying how this technology can be used to improve immune cell tracking with MRI and investigate current and new tools for evaluating immunotherapies that can be applied to the clinic. Together with Cubresa, we plan to develop PET/MRI applications that improve and accelerate the translation of immunotherapies.

Faculty Supervisor:

Kimberly Brewer


Marie-Laurence Tremblay


Cubresa Inc.




Medical devices




Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects